Milestone Pharmaceuticals Inc. - Common Shares — 四半期キャッシュフロー (NASDAQ:MIST) | MetaTrader

チャート全体を表示 Full chart

Financials

概要明細書統計

総資産 75.5 M61.88 M47.42 M87.75 M113.56 M193.73 M 負債合計 62.35 M68.01 M65.16 M67.25 M71.79 M157.69 M 純資産合計 13.15 M-6.12 M-17.75 M20.5 M41.77 M36.05 M 負債および純資産合計 75.5 M61.88 M47.42 M87.75 M113.56 M193.73 M 有利子負債合計 —————— 純負債 ——————

ニュース

Milestone Pharmaceuticals Inc. (MIST) Q1 2026 Earnings Call Transcript

Milestone Reports Q1 Results, Highlights Initial CARDAMYST Sales - Milestone Pharmaceuticals (NASDAQ:MIST

Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates

Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call Transcript

Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Milestone Pharmaceuticals (NASDAQ:MIST)

Milestone Stock: Downgrading To Sell As CARDAMYST Faces A Tough Reality (NASDAQ:MIST)

Milestone Pharmaceuticals appoints David Sandoval as general counsel

All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy

Milestone’s PSVT treatment CARDAMYST now available in US pharmacies

Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense (MIST)

アプターの点鼻スプレーシステム、新承認のPSVT治療薬の投与に採用

Milestone Pharmaceuticals: Cardamyst Beat Placebo, But The Commercial Bar Is Higher (MIST)